Other partner genes with KAT6A, such as NCOA2 have been reported in invasive ductal breast carcinoma, prostate, bladder, and colon cancers and AML in mouse models, NCOA3 with M5 AML, and ASXL2 with therapy-related AML in a 6-year-old with M2 AML treated with etoposide.[17–19] Coenen et al[14] studied a large cohort of patients with KAT6A::CREBBP fusion (n = 63) and reported spontaneous remission in 7 patients, of whom 3 remained in continuous remission; the 5 year overall survival rate was 59%. Here, NCOA3 is linked to invasive ductal breast carcinoma.